Cargando…
DEVELOPMENT OF EPIGENETIC MEASURES FOR GEROSCIENCE CLINICAL TRIALS
One of the major goals of the NIA is to oversee development of biomarkers of aging. In recent years, DNA methylation has emerged as a promising avenue from which to quantify biological age. We and others have shown that these measures track age across various tissues and cells, and further deviation...
Autor principal: | Levine, Morgan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841242/ http://dx.doi.org/10.1093/geroni/igz038.2732 |
Ejemplares similares
-
BIOMARKER STRATEGIES FOR GEROSCIENCE-GUIDED CLINICAL TRIALS
por: Justice, Jamie N, et al.
Publicado: (2019) -
INTEREST GROUP SESSION—GEROSCIENCE: METHODS FROM BENCH TO POPULATION SCIENCE TO INFORM CONSTRUCTION OF GEROSCIENCE CLINICAL TRIALS
por: Sanders, Jason L, et al.
Publicado: (2019) -
USING OBSERVATIONAL DATA TO INFORM CANDIDATE PHENOTYPES FOR GEROSCIENCE TRIALS
por: Sanders, Jason L, et al.
Publicado: (2019) -
CLINICAL TRIALS IN GEROSCIENCE
por: Kaeberlein, Matt, et al.
Publicado: (2019) -
SENOLYTIC DRUGS: DISCOVERY, TRANSLATION, AND APPLICATION
por: LeBrasseur, Nathan
Publicado: (2019)